Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | (Q3)Oct 31, 2023 | (Q2)Jul 31, 2023 | (Q1)Apr 30, 2023 | (FY)Jan 31, 2023 | (Q4)Jan 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 38.07%1T | 43.48%1.08T | 9.71%777.05B | 6.09%3.11T | 14.90%917.73B | 2.92%727.07B | 10.91%754.16B | -4.76%708.28B | 13.10%2.93T | 7.25%798.76B |
Cost of revenue | 40.29%810.74B | 47.21%881.54B | 8.03%616.01B | 5.93%2.48T | 12.84%736.5B | 1.41%577.92B | 10.59%598.85B | -1.77%570.23B | 13.77%2.34T | 8.85%652.66B |
Gross profit | 29.50%193.15B | 29.11%200.53B | 16.66%161.05B | 6.75%623.75B | 24.06%181.24B | 9.21%149.14B | 12.17%155.32B | -15.40%138.05B | 10.48%584.3B | 0.63%146.09B |
Operating expense | 34.67%117.66B | 33.64%115.11B | 8.52%89.33B | 9.29%352.79B | 11.33%96.97B | 8.55%87.37B | 7.93%86.13B | 9.16%82.31B | 8.07%322.81B | 4.64%87.1B |
Selling and administrative expenses | ---- | ---- | ---- | 9.29%352.79B | ---- | ---- | ---- | ---- | 8.07%322.81B | ---- |
-Selling and marketing expense | ---- | ---- | ---- | 7.57%58.94B | ---- | ---- | ---- | ---- | -2.22%54.79B | ---- |
-General and administrative expense | ---- | ---- | ---- | 9.64%293.85B | ---- | ---- | ---- | ---- | 10.44%268.02B | ---- |
Operating profit | 22.20%75.48B | 23.48%85.43B | 28.67%71.72B | 3.62%270.96B | 42.85%84.27B | 10.16%61.77B | 17.94%69.18B | -36.50%55.74B | 13.61%261.49B | -4.76%58.99B |
Net non-operating interest income (expenses) | -148.79%-7.51B | -281.01%-6.4B | -100.24%-4.23B | -210.72%-9.42B | -122.85%-2.61B | -132.79%-3.02B | -1,050.68%-1.68B | -405.50%-2.11B | -146.19%-3.03B | -41.50%-1.17B |
Non-operating interest income | 360.29%2.89B | 185.39%2.68B | 27.05%526M | 29.03%2.95B | 30.46%968M | 71.78%627M | 18.88%938M | 6.70%414M | -12.29%2.28B | -2.24%742M |
Non-operating interest expense | 185.18%10.39B | 246.75%9.08B | 88.25%4.76B | 132.67%12.37B | 87.05%3.58B | 119.39%3.64B | 180.00%2.62B | 213.52%2.53B | 38.61%5.32B | 20.59%1.92B |
Net investment income | -106.78%-173M | -65.93%943M | 372.61%3.37B | 372.25%6.48B | 116.09%453M | 275.70%2.55B | -10.54%2.77B | 71.57%712M | -54.81%1.37B | -485.09%-2.82B |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 910.47%18.83B | -82.69%116M | 2,029.00%5.73B | 656.99%2.11B | 1.08B | 18,730.00%1.86B | 670M | -75.41%269M | -22.07%279M |
Income from associates and other participating interests | -496.73%-913M | -81.68%469M | 96.04%-23M | 191.04%1.9B | 125.34%74M | -593.55%-153M | 6,195.24%2.56B | 67.43%-581M | -68.58%-2.09B | 25.32%-292M |
Special income (charges) | -71.42%579M | -718.09%-4.12B | -103.16%-248M | 47.33%14.98B | 256.19%5.62B | -75.29%2.03B | -106.21%-503M | 410.08%7.84B | 223.16%10.17B | -242.25%-3.6B |
Less:Restructuring and mergern&acquisition | ---37M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Less:Other special charges | 63.13%-542M | 84.00%736M | 102.96%236M | 1.49%-14.84B | -779.32%-5.78B | 82.11%-1.47B | 104.88%400M | -1,696.80%-7.98B | -308.55%-15.06B | 48.52%851M |
Less:Write off | --0 | --0 | -91.55%12M | -103.03%-148M | -94.06%163M | -2,747.62%-556M | 10.75%103M | -93.00%142M | 807.05%4.89B | 474.48%2.75B |
Other non-operating income (expenses) | -609.36%-1.36B | -518.90%-4.26B | 125.84%170M | -256.08%-1.67B | -823.44%-591M | 152.56%267M | -1,811.11%-688M | -573.38%-658M | 26.03%-469M | -64M |
Income before tax | 2.46%66.11B | 23.65%90.89B | 15.02%70.86B | 7.94%288.96B | 74.02%89.32B | 2.14%64.53B | 5.58%73.5B | -26.30%61.61B | 14.24%267.71B | -15.52%51.33B |
Income tax | 60.87%23.57B | -20.84%17.44B | 5.46%19.46B | 6.61%81.43B | 64.44%26.29B | -12.14%14.65B | 3.02%22.04B | -17.35%18.45B | 8.62%76.38B | -19.79%15.99B |
Net income | -14.71%42.54B | 42.70%73.45B | 19.11%51.4B | 8.47%207.53B | 78.36%63.03B | 7.26%49.87B | 6.71%51.47B | -29.56%43.16B | 16.65%191.33B | -13.43%35.34B |
Net income continuous operations | -14.71%42.54B | 42.70%73.45B | 19.11%51.4B | 8.47%207.53B | 78.36%63.03B | 7.26%49.87B | 6.72%51.47B | -29.56%43.16B | 16.65%191.33B | -13.43%35.34B |
Noncontrolling interests | 45.40%695M | -2.20%888M | -20.15%975M | -23.61%5.2B | 310.13%2.59B | -36.44%478M | -44.80%908M | -67.67%1.22B | -32.67%6.81B | -77.50%632M |
Net income attributable to the company | -15.29%41.84B | 43.50%72.56B | 20.25%50.43B | 9.65%202.33B | 74.14%60.44B | 7.97%49.4B | 8.54%50.56B | -27.05%41.93B | 19.89%184.52B | -8.70%34.71B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -15.29%41.84B | 43.50%72.56B | 20.25%50.43B | 9.65%202.33B | 74.14%60.44B | 7.97%49.4B | 8.54%50.56B | -27.05%41.93B | 19.89%184.52B | -8.70%34.71B |
Gross dividend payment | ||||||||||
Basic earnings per share | -15.02%64.57 | 45.44%111.96 | 22.90%77.83 | 11.83%309.29 | 77.04%93 | 10.13%75.98 | 10.51%76.98 | -25.84%63.33 | 21.64%276.58 | -6.71%52.53 |
Diluted earnings per share | -15.02%64.55 | 45.45%111.94 | 22.89%77.8 | 11.84%309.19 | 77.10%92.96 | 10.13%75.96 | 10.51%76.96 | -25.83%63.31 | 21.65%276.46 | -6.73%52.49 |
Dividend per share | 0 | 8.47%64 | 0 | 11.82%123 | 10.34%64 | 0 | 13.46%59 | 0 | 22.22%110 | 23.40%58 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |